This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Gorbach, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snydman, D. R.
Right arrow Articles by Gorbach, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1649-1655, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01435-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004{triangledown}

D. R. Snydman,1* N. V. Jacobus,1 L. A. McDermott,1 R. Ruthazer,1 Y. Golan,1 E. J. C. Goldstein,2 S. M. Finegold,3 L. J. Harrell,4 D. W. Hecht,5 S. G. Jenkins,6 C. Pierson,7 R. Venezia,8 V. Yu,9 J. Rihs,9 and S. L. Gorbach1

Departments of Medicine, Community Health and Clinical Research, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts,1 R. M. Alden Research Laboratories, Santa Monica, California,2 Wadsworth Veterans Administration Hospital, Los Angeles, California,3 Duke University Medical Center, Durham, North Carolina,4 Loyola University Medical Center, Maywood, Illinois,5 Carolinas Medical Center, Charlotte, North Carolina, and Mt. Sinai Medical Center, New York, New York,6 University of Michigan Medical Center, Ann Arbor, Michigan,7 Albany Medical Center, Albany, New York,8 Pittsburgh Veterans Administration Medical Center, Pittsburgh, Pennsylvania9

Received 16 November 2006/ Returned for modification 17 December 2006/ Accepted 28 January 2007

The susceptibility trends for the species of the Bacteroides fragilis group against various antibiotics from 1997 to 2004 were determined by using data for 5,225 isolates referred by 10 medical centers. The antibiotic test panel included ertapenem, imipenem, meropenem, ampicillin-sulbactam, piperacillin-tazobactam, cefoxitin, clindamycin, moxifloxacin, tigecycline, chloramphenicol, and metronidazole. From 1997 to 2004 there were decreases in the geometric mean (GM) MICs of imipenem, meropenem, piperacillin-tazobactam, and cefoxitin for many of the species within the group. B. distasonis showed the highest rates of resistance to most of the β-lactams. B. fragilis, B. ovatus, and B. thetaiotaomicron showed significantly higher GM MICs and rates of resistance to clindamycin over time. The rate of resistance to moxifloxacin of B. vulgatus was very high (MIC range for the 8-year study period, 38% to 66%). B. fragilis, B. ovatus, and B. distasonis and other Bacteroides spp. exhibited significant increases in the rates of resistance to moxifloxacin over the 8 years. Resistance rates and GM MICs for tigecycline were low and stable during the 5-year period over which this agent was studied. All isolates were susceptible to chloramphenicol (MICs < 16 µg/ml). In 2002, one isolate resistant to metronidazole (MIC = 64 µg/ml) was noted. These data indicate changes in susceptibility over time; surprisingly, some antimicrobial agents are more active now than they were 5 years ago.

* Corresponding author. Mailing address: Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, 750 Washington Street, Box 238, Boston, MA 02111. Phone: (617) 636-5788. Fax: (617) 636-8525. E-mail: dsnydman{at}tufts-nemc.org

{triangledown} Published ahead of print on 5 February 2007.

Antimicrobial Agents and Chemotherapy, May 2007, p. 1649-1655, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01435-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Snydman, D. R., Jacobus, N. V., McDermott, L. A. (2008). In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 52: 4492-4496 [Abstract] [Full Text]  
  • Liu, C.-Y., Huang, Y.-T., Liao, C.-H., Yen, L.-C., Lin, H.-Y., Hsueh, P.-R. (2008). Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems. Antimicrob. Agents Chemother. 52: 3161-3168 [Abstract] [Full Text]  
  • (2008). What role for {blacktriangledown}tigecycline in infections?. DTB 46: 62-64 [Abstract] [Full Text]  
  • Papaparaskevas, J., Pantazatou, A., Katsandri, A., Houhoula, D. P., Legakis, N. J., Tsakris, A., Avlamis, A. (2008). Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 62: 137-141 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Lopez, F., Rodriguez-Avial, I., Picazo, J. J. (2008). Resistance Trends of the Bacteroides fragilis Group over a 10-Year Period, 1997 to 2006, in Madrid, Spain. Antimicrob. Agents Chemother. 52: 2686-2690 [Abstract] [Full Text]  
  • Simmon, K. E., Mirrett, S., Reller, L. B., Petti, C. A. (2008). Genotypic Diversity of Anaerobic Isolates from Bloodstream Infections. J. Clin. Microbiol. 46: 1596-1601 [Abstract] [Full Text]  
  • Wexler, H. M. (2007). Bacteroides: the Good, the Bad, and the Nitty-Gritty. Clin. Microbiol. Rev. 20: 593-621 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»